“Comparing such estimates from the community, home device monitoring may result in another approximately 200,000 people retaining good functional vision,” Dr. Regillo said.
When an estimation of those who are at high risk for developing CNV and can use the device, between 100,000 to 300,000 additional patients in the United States would be detected at 20/40 or better over the next 5 years. The potential impact on public health in the United States may be considerable with more than 60% of patients likely to maintain 20/40 or better for at least 2 years on anti-vascular endothelial growth factor therapy, Dr. Regillo noted.
The usability of the device by older patients is a consideration. A recent study from the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, supported use of the device in this study population and showed that usability was high, i.e., more than 80% and not associated with age (Chaikitmongkol V et al. Retin Cases Brief Rep. 2015;9:33-37).